Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

In such cases, polyclonal antibodies purified from naturally ... antigen molecules specifically modified to enhance immunogenicity; antigen molecules targeted to antigen-presenting cells; and ...

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...

Serum samples for anti-panitumumab antibody testing were collected from mCRC patients enrolled in 4 panitumumab clinical trials (20050184, 20060277, 20050181, and 20050203). Patients in these ...

The European Commission (EC) has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, ...

The purpose of this analysis was to examine the immunogenicity of panitumumab and to evaluate the effect of anti-panitumumab antibodies on pharmacokinetic and safety profiles in patients with mCRC ...

This whitepaper explores how innovative chromatography solutions can improve aggregate removal while maintaining high product purity and yield, reducing both processing time and costs.

While monoclonal antibodies have proven to be highly effective in various applications, there are still challenges to overcome. One of the main challenges is the potential immunogenicity of monoclonal ...

and low immunogenicity, reducing the risk of adverse immune reactions. Camelid antibodies have been shown to exhibit enhanced sensitivity and specificity in diagnostic systems for detecting cancer ...